Joseph A Ware
Overview
Explore the profile of Joseph A Ware including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, de Jong A, et al.
Clin Pharmacol Drug Dev
. 2022 Aug;
11(11):1294-1307.
PMID: 36029150
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the...
2.
Sharma S, Pepin X, Cheung J, Zheng L, Wei H, Townsley D, et al.
Br J Clin Pharmacol
. 2022 Apr;
88(10):4573-4584.
PMID: 35466438
Aims: Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. Many critically ill patients are unable to swallow and...
3.
Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, et al.
J Clin Pharmacol
. 2021 Dec;
62(6):812-822.
PMID: 34897701
Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic...
4.
Gadkar K, Friedrich C, Hurez V, Ruiz M, Dickmann L, Jolly M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Dec;
11(5):616-627.
PMID: 34850607
Several PI3K inhibitors are in clinical development for the treatment of various forms of cancers, including pan-PI3K inhibitors targeting all four PI3K isoforms (α, β, γ, and δ), and isoform-selective...
5.
Pilla Reddy V, Fretland A, Zhou D, Sharma S, Chen B, Vishwanathan K, et al.
Cancer Chemother Pharmacol
. 2021 Jun;
88(3):451-464.
PMID: 34080039
Purpose: Limited information is available regarding the drug-drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy. The addition of...
6.
Yue Q, Khojasteh S, Cho S, Ma S, Mulder T, Chen J, et al.
Xenobiotica
. 2021 May;
51(7):796-810.
PMID: 33938357
The absorption, metabolism and excretion of pictilisib, a selective small molecule inhibitor of class 1 A phosphoinositide 3-kinase (PI3K), was characterized following a single oral administration of [C]pictilisib in rats,...
7.
Reyner E, Lum B, Jing J, Kagedal M, Ware J, Dickmann L
Clin Transl Sci
. 2019 Nov;
13(2):410-418.
PMID: 31729137
Pharmacokinetic (PK) variability in cancer clinical trials may be due to heterogeneous populations and identifying sources of variability is important. Use of healthy subjects in clinical pharmacology studies together with...
8.
Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, et al.
Br J Clin Pharmacol
. 2019 Apr;
85(8):1751-1760.
PMID: 30973970
Aims: Navoximod (GDC-0919, NLG-919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were...
9.
Zamek-Gliszczynski M, Chu X, Cook J, Custodio J, Galetin A, Giacomini K, et al.
Clin Pharmacol Ther
. 2018 May;
104(5):781-784.
PMID: 29761830
Metformin drug-drug interaction (DDI) studies are conducted during development of drugs that inhibit organic cation transporters and/or multidrug and toxin extrusion proteins (OCTs/MATEs). Monitoring solely changes in systemic exposure, the...
10.
Evers R, Piquette-Miller M, Polli J, Russel F, Sprowl J, Tohyama K, et al.
Clin Pharmacol Ther
. 2018 May;
104(5):900-915.
PMID: 29756222
Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds. Therefore, disruption of these pathways by inhibition, induction, genetic polymorphisms, or...